Last reviewed · How we verify
Isocain (PROCAINE)
At a glance
| Generic name | PROCAINE |
|---|---|
| Sponsor | Pfizer |
| Drug class | Amide Local Anesthetic [EPC] |
| Target | 5-hydroxytryptamine receptor 3A |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | FDA-approved |
| First approval | 1954 |
Approved indications
- Tattoo Removal
- Waxing
- Hair Removal
Common side effects
- Nervousness
- Dizziness
- Blurred vision
- Tremors
- Drowsiness
- Sweating
- Feeling of faintness
- Cutaneous lesions
- Urticaria
- Edema
- Localized puffiness
- Localized swelling
Serious adverse events
- Convulsions
- Unconsciousness
- Respiratory arrest
- Cerebral hypoxia
- Seizure
- Cardiovascular catastrophe
- Anaphylactoid reactions
Key clinical trials
- Oral Amoxicillin Compared to Penicillin G Benzathine for the Treatment of Acquired Syphilis. (PHASE3)
- § Procaine Periarticular Injections for Pain Reduction in Elderly With Osteoarthritis (PHASE3)
- Exploring Long-term Pain Relief with 5% Dextrose Added to Local Anesthetic (NA)
- Virtual Reality in Plastic Surgery: Pain Control and Augmented Satisfaction
- Trial to Assess Chelation Therapy in Critical Limb Ischemia (PHASE3)
- Efficacy of the Use of Cellular Matrix/ A-CP-HA Kit (PHASE4)
- A Prospective Clinical Study on the Safety and Efficacy of Radiofrequency Ablation for the Treatment of Patients With Desmoid Tumors (NA)
- Mesotherapy in the Treatment of Chronic Migraine (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Isocain CI brief — competitive landscape report
- Isocain updates RSS · CI watch RSS
- Pfizer portfolio CI